BACKGROUND: We compared the incidence of prostate cancer in first-degree family members of African-Americans with that in white Americans. METHODS: A historical cohort design was used to enroll 330 incident cases <80 years of age that were diagnosed at the Houston VA Medical Center between June 9, 1993 and June 8, 1996. We compared incidence rates in the probands' families with the incidence rates found in contemporaneous data from the national and regional Surveillance, Epidemiology, and End-Results (SEER) program. RESULTS: Three-hundred five probands (41% African-American) had evaluable first-degree relatives (394 African-American, 527 non-African-American). The standardized incidence ratio was 1.61 overall (95% confidence interval (CI): 1.22-2.13) and did not differ between African-American and non-African-American families: 1.58 (1.05-2.29) and 1.65 (1.06-2.45) in African-Americans and non-African-Americans, respectively. CONCLUSIONS: The similar level of familial aggregation is evidence that the higher incidence of prostate cancer in African-Americans is not attributable to a higher prevalence of germline mutations predisposing to the disease. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: We compared the incidence of prostate cancer in first-degree family members of African-Americans with that in white Americans. METHODS: A historical cohort design was used to enroll 330 incident cases <80 years of age that were diagnosed at the Houston VA Medical Center between June 9, 1993 and June 8, 1996. We compared incidence rates in the probands' families with the incidence rates found in contemporaneous data from the national and regional Surveillance, Epidemiology, and End-Results (SEER) program. RESULTS: Three-hundred five probands (41% African-American) had evaluable first-degree relatives (394 African-American, 527 non-African-American). The standardized incidence ratio was 1.61 overall (95% confidence interval (CI): 1.22-2.13) and did not differ between African-American and non-African-American families: 1.58 (1.05-2.29) and 1.65 (1.06-2.45) in African-Americans and non-African-Americans, respectively. CONCLUSIONS: The similar level of familial aggregation is evidence that the higher incidence of prostate cancer in African-Americans is not attributable to a higher prevalence of germline mutations predisposing to the disease. Copyright 2003 Wiley-Liss, Inc.
Authors: Irina Mordukhovich; Paul L Reiter; Danielle M Backes; Leila Family; Lauren E McCullough; Katie M O'Brien; Hilda Razzaghi; Andrew F Olshan Journal: Cancer Causes Control Date: 2010-12-24 Impact factor: 2.506
Authors: R A Kittles; A B Baffoe-Bonnie; T Y Moses; C M Robbins; C Ahaghotu; P Huusko; C Pettaway; S Vijayakumar; J Bennett; G Hoke; T Mason; S Weinrich; J M Trent; F S Collins; S Mousses; J Bailey-Wilson; P Furbert-Harris; G Dunston; I J Powell; J D Carpten Journal: J Med Genet Date: 2005-09-09 Impact factor: 6.318
Authors: Jeannette T Bensen; Zongli Xu; Gary J Smith; James L Mohler; Elizabeth T H Fontham; Jack A Taylor Journal: Prostate Date: 2012-05-01 Impact factor: 4.104
Authors: Joke Beuten; Jonathan A L Gelfond; Jennifer L Franke; Stacey Shook; Teresa L Johnson-Pais; Ian M Thompson; Robin J Leach Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01-19 Impact factor: 4.254
Authors: Lauren Barber; Travis Gerke; Sarah C Markt; Samuel F Peisch; Kathryn M Wilson; Thomas Ahearn; Edward Giovannucci; Giovanni Parmigiani; Lorelei A Mucci Journal: Clin Cancer Res Date: 2018-08-06 Impact factor: 12.531
Authors: Charnita M Zeigler-Johnson; Elaine Spangler; Mohamed Jalloh; Serigne M Gueye; Hanna Rennert; Timothy R Rebbeck Journal: Can J Urol Date: 2008-02 Impact factor: 1.344
Authors: Lara E Sucheston; Jeannette T Bensen; Zongli Xu; Prashant K Singh; Leah Preus; James L Mohler; L Joseph Su; Elizabeth T H Fontham; Bernardo Ruiz; Gary J Smith; Jack A Taylor Journal: PLoS One Date: 2012-03-27 Impact factor: 3.240